iPLEDGE Weaknesses

Is It Time to Address the Flaws?

Amanda A. Cyrulnik, Aron J. Gewirtzman, Karin Blecher Paz, Jaimie B. Glick, Anika K. Anam, Daniel A. Carrasco, Alan R. Shalita, Steven R. Cohen

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The observance during acne follow-ups that information stored within iPLEDGE was discordant with medical charts prompted this study.

OBJECTIVE: To evaluate the information acquired and stored within iPLEDGE as it compares to medical charts with a goal of assessing the efficacy of iPLEDGE as a database.

METHODS: This is a multicenter retrospective chart review analyzing congruence and discrepancies between medical chart documentation and iPLEDGE data for all patients who received at least a single dose of isotretinoin from the primary investigators between January 2006 and November 2010.

RESULTS: A total of 357 charts were analyzed. Overall congruence between medical chart documentation and iPLEDGE data was observed in only 73.1% of cases. The discrepancy (N=96) was due to a missed dose (prescription recorded in chart but not in iPLEDGE) in 81.4% of cases, or an addition (medication dispensed per iPLEDGE without corresponding chart documentation) in the remainder of cases. Of note, several charts had multiple discrepancies (N=249 total discrepancies).

LIMITATIONS: Retrospective chart review study.

CONCLUSION: Given the large percentage of discordant data, our findings question the efficacy of the iPLEDGE system, which is designed to monitor every dispensed isotretinoin dose.

Original languageEnglish (US)
Pages (from-to)97-102
Number of pages6
JournalJournal of drugs in dermatology : JDD
Volume15
Issue number1
StatePublished - Jan 1 2016

Fingerprint

Documentation
Isotretinoin
Acne Vulgaris
Prescriptions
Research Personnel
Databases

ASJC Scopus subject areas

  • Medicine(all)
  • Dermatology

Cite this

iPLEDGE Weaknesses : Is It Time to Address the Flaws? / Cyrulnik, Amanda A.; Gewirtzman, Aron J.; Blecher Paz, Karin; Glick, Jaimie B.; Anam, Anika K.; Carrasco, Daniel A.; Shalita, Alan R.; Cohen, Steven R.

In: Journal of drugs in dermatology : JDD, Vol. 15, No. 1, 01.01.2016, p. 97-102.

Research output: Contribution to journalArticle

Cyrulnik, AA, Gewirtzman, AJ, Blecher Paz, K, Glick, JB, Anam, AK, Carrasco, DA, Shalita, AR & Cohen, SR 2016, 'iPLEDGE Weaknesses: Is It Time to Address the Flaws?', Journal of drugs in dermatology : JDD, vol. 15, no. 1, pp. 97-102.
Cyrulnik AA, Gewirtzman AJ, Blecher Paz K, Glick JB, Anam AK, Carrasco DA et al. iPLEDGE Weaknesses: Is It Time to Address the Flaws? Journal of drugs in dermatology : JDD. 2016 Jan 1;15(1):97-102.
Cyrulnik, Amanda A. ; Gewirtzman, Aron J. ; Blecher Paz, Karin ; Glick, Jaimie B. ; Anam, Anika K. ; Carrasco, Daniel A. ; Shalita, Alan R. ; Cohen, Steven R. / iPLEDGE Weaknesses : Is It Time to Address the Flaws?. In: Journal of drugs in dermatology : JDD. 2016 ; Vol. 15, No. 1. pp. 97-102.
@article{88eb31aa441d4b2d87cc2d812d641319,
title = "iPLEDGE Weaknesses: Is It Time to Address the Flaws?",
abstract = "BACKGROUND: The observance during acne follow-ups that information stored within iPLEDGE was discordant with medical charts prompted this study.OBJECTIVE: To evaluate the information acquired and stored within iPLEDGE as it compares to medical charts with a goal of assessing the efficacy of iPLEDGE as a database.METHODS: This is a multicenter retrospective chart review analyzing congruence and discrepancies between medical chart documentation and iPLEDGE data for all patients who received at least a single dose of isotretinoin from the primary investigators between January 2006 and November 2010.RESULTS: A total of 357 charts were analyzed. Overall congruence between medical chart documentation and iPLEDGE data was observed in only 73.1{\%} of cases. The discrepancy (N=96) was due to a missed dose (prescription recorded in chart but not in iPLEDGE) in 81.4{\%} of cases, or an addition (medication dispensed per iPLEDGE without corresponding chart documentation) in the remainder of cases. Of note, several charts had multiple discrepancies (N=249 total discrepancies).LIMITATIONS: Retrospective chart review study.CONCLUSION: Given the large percentage of discordant data, our findings question the efficacy of the iPLEDGE system, which is designed to monitor every dispensed isotretinoin dose.",
author = "Cyrulnik, {Amanda A.} and Gewirtzman, {Aron J.} and {Blecher Paz}, Karin and Glick, {Jaimie B.} and Anam, {Anika K.} and Carrasco, {Daniel A.} and Shalita, {Alan R.} and Cohen, {Steven R.}",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "15",
pages = "97--102",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "1",

}

TY - JOUR

T1 - iPLEDGE Weaknesses

T2 - Is It Time to Address the Flaws?

AU - Cyrulnik, Amanda A.

AU - Gewirtzman, Aron J.

AU - Blecher Paz, Karin

AU - Glick, Jaimie B.

AU - Anam, Anika K.

AU - Carrasco, Daniel A.

AU - Shalita, Alan R.

AU - Cohen, Steven R.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - BACKGROUND: The observance during acne follow-ups that information stored within iPLEDGE was discordant with medical charts prompted this study.OBJECTIVE: To evaluate the information acquired and stored within iPLEDGE as it compares to medical charts with a goal of assessing the efficacy of iPLEDGE as a database.METHODS: This is a multicenter retrospective chart review analyzing congruence and discrepancies between medical chart documentation and iPLEDGE data for all patients who received at least a single dose of isotretinoin from the primary investigators between January 2006 and November 2010.RESULTS: A total of 357 charts were analyzed. Overall congruence between medical chart documentation and iPLEDGE data was observed in only 73.1% of cases. The discrepancy (N=96) was due to a missed dose (prescription recorded in chart but not in iPLEDGE) in 81.4% of cases, or an addition (medication dispensed per iPLEDGE without corresponding chart documentation) in the remainder of cases. Of note, several charts had multiple discrepancies (N=249 total discrepancies).LIMITATIONS: Retrospective chart review study.CONCLUSION: Given the large percentage of discordant data, our findings question the efficacy of the iPLEDGE system, which is designed to monitor every dispensed isotretinoin dose.

AB - BACKGROUND: The observance during acne follow-ups that information stored within iPLEDGE was discordant with medical charts prompted this study.OBJECTIVE: To evaluate the information acquired and stored within iPLEDGE as it compares to medical charts with a goal of assessing the efficacy of iPLEDGE as a database.METHODS: This is a multicenter retrospective chart review analyzing congruence and discrepancies between medical chart documentation and iPLEDGE data for all patients who received at least a single dose of isotretinoin from the primary investigators between January 2006 and November 2010.RESULTS: A total of 357 charts were analyzed. Overall congruence between medical chart documentation and iPLEDGE data was observed in only 73.1% of cases. The discrepancy (N=96) was due to a missed dose (prescription recorded in chart but not in iPLEDGE) in 81.4% of cases, or an addition (medication dispensed per iPLEDGE without corresponding chart documentation) in the remainder of cases. Of note, several charts had multiple discrepancies (N=249 total discrepancies).LIMITATIONS: Retrospective chart review study.CONCLUSION: Given the large percentage of discordant data, our findings question the efficacy of the iPLEDGE system, which is designed to monitor every dispensed isotretinoin dose.

UR - http://www.scopus.com/inward/record.url?scp=85020320341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020320341&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 97

EP - 102

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 1

ER -